<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">07-PONE-RA-02780R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005689</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cell Biology</subject><subject>Pharmacology</subject><subject>Public Health and Epidemiology</subject><subject>Respiratory Medicine</subject><subject>Surgery</subject><subject>Non-Clinical Medicine/Health Policy</subject><subject>Public Health and Epidemiology/Environmental Health</subject><subject>Public Health and Epidemiology/Occupational and Industrial Medicine</subject></subj-group></article-categories><title-group><article-title>Systemic Inhibition of NF-&#x003ba;B Activation Protects from Silicosis</article-title><alt-title alt-title-type="running-head">NF-&#x003ba;B in Silicosis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Di Giuseppe</surname><given-names>Michelangelo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gambelli</surname><given-names>Federica</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hoyle</surname><given-names>Gary W.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lungarella</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Studer</surname><given-names>Sean M.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Richards</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yousem</surname><given-names>Sam</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>McCurry</surname><given-names>Ken</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dauber</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kaminski</surname><given-names>Naftali</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Leikauf</surname><given-names>George</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ortiz</surname><given-names>Luis A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Division of Occupational and Environmental Medicine, Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Environmental and Occupational Health Sciences, School of Public Health and Informational Sciences, University of Louisville, Louisville, Kentucky, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Physiopathology, University of Siena, Siena, Italy</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Simmons Center for Interstitial Lung Disease, Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Department of Thoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Barnes</surname><given-names>Peter J.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">National Heart and Lung Institute, Imperial College London, United Kingdom</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>lao1@pitt.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: FG GWH GDL LAO. Performed the experiments: MDG FG GWH SAY NK GDL LAO. Analyzed the data: MDG FG GWH GL SMS TJR SAY JD NK GDL LAO. Contributed reagents/materials/analysis tools: MDG GWH GL SMS SAY KRM JD NK GDL LAO. Wrote the paper: NK GDL LAO. Enrolled patients: LAO.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>25</day><month>5</month><year>2009</year></pub-date><volume>4</volume><issue>5</issue><elocation-id>e5689</elocation-id><history><date date-type="received"><day>16</day><month>11</month><year>2007</year></date><date date-type="accepted"><day>7</day><month>4</month><year>2009</year></date></history><copyright-statement>Di Giuseppe et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>Silicosis is a complex lung disease for which no successful treatment is available and therefore lung transplantation is a potential alternative. Tumor necrosis factor alpha (TNF&#x003b1;) plays a central role in the pathogenesis of silicosis. TNF&#x003b1; signaling is mediated by the transcription factor, Nuclear Factor (NF)-&#x003ba;B, which regulates genes controlling several physiological processes including the innate immune responses, cell death, and inflammation. Therefore, inhibition of NF-&#x003ba;B activation represents a potential therapeutic strategy for silicosis.</p></sec><sec><title>Methods/Findings</title><p>In the present work we evaluated the lung transplant database (May 1986&#x02013;July 2007) at the University of Pittsburgh to study the efficacy of lung transplantation in patients with silicosis (n&#x0200a;&#x0003d;&#x0200a;11). We contrasted the overall survival and rate of graft rejection in these patients to that of patients with idiopathic pulmonary fibrosis (IPF, n&#x0200a;&#x0003d;&#x0200a;79) that was selected as a control group because survival benefit of lung transplantation has been identified for these patients. At the time of lung transplantation, we found the lungs of silica-exposed subjects to contain multiple foci of inflammatory cells and silicotic nodules with proximal TNF&#x003b1; expressing macrophage and NF-&#x003ba;B activation in epithelial cells. Patients with silicosis had poor survival (median survival 2.4 yr; confidence interval (CI): 0.16&#x02013;7.88 yr) compared to IPF patients (5.3 yr; CI: 2.8&#x02013;15 yr; p&#x0200a;&#x0003d;&#x0200a;0.07), and experienced early rejection of their lung grafts (0.9 yr; CI: 0.22&#x02013;0.9 yr) following lung transplantation (2.4 yr; CI:1.5&#x02013;3.6 yr; p&#x0003c;0.05). Using a mouse experimental model in which the endotracheal instillation of silica reproduces the silica-induced lung injury observed in humans we found that systemic inhibition of NF-&#x003ba;B activation with a pharmacologic inhibitor (BAY 11-7085) of I&#x003ba;B&#x003b1; phosphorylation decreased silica-induced inflammation and collagen deposition. In contrast, transgenic mice expressing a dominant negative I&#x003ba;B&#x003b1; mutant protein under the control of epithelial cell specific promoters demonstrate enhanced apoptosis and collagen deposition in their lungs in response to silica.</p></sec><sec><title>Conclusions</title><p>Although limited by its size, our data support that patients with silicosis appear to have poor outcome following lung transplantation. Experimental data indicate that while the systemic inhibition of NF-&#x003ba;B protects from silica-induced lung injury, epithelial cell specific NF-&#x003ba;B inhibition appears to aggravate the outcome of experimental silicosis.</p></sec></abstract><counts><page-count count="14"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Chronic occupational or environmental exposure to silica is associated with the development of silicosis, a lung disease characterized by granulomatous inflammation and pulmonary fibrosis <xref ref-type="bibr" rid="pone.0005689-American1">&#x0005b;1&#x0005d;</xref>. In spite of significant progress in its prevention, silicosis remains a major global health problem associated with a high morbidity and mortality for which no specific therapy is available <xref ref-type="bibr" rid="pone.0005689-American1">&#x0005b;1&#x0005d;</xref>. Silica-induced inflammation is a complex process in which the interaction of silica particles with lung cells is followed by the release of inflammatory mediators <xref ref-type="bibr" rid="pone.0005689-Mossman1">&#x0005b;2&#x0005d;</xref>. Among these mediators, tumor necrosis factor alpha (TNF&#x003b1;) plays a fundamental role in the pathogenesis of silica-induced lung injury. Mice exposed to silica demonstrate enhanced TNF&#x003b1; production in their lungs in a manner that precedes the inflammatory response and the accumulation of lung collagen <xref ref-type="bibr" rid="pone.0005689-Piguet1">&#x0005b;3&#x0005d;</xref>.</p><p>NF-&#x003ba;B is a transcription factor that plays a fundamental role in inflammation <xref ref-type="bibr" rid="pone.0005689-Baeuerle1">&#x0005b;4&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005689-Perkins1">&#x0005b;6&#x0005d;</xref>. NF-&#x003ba;B is a protein complex formed from the homo or heterodimers of any of the five members of the rel transcription factor family &#x0005b;REL (c-Rel), RELA (p65), RELB (Rel B), NFKB1 (p50/p105), and NFKB2 (p52/p100)&#x0005d; <xref ref-type="bibr" rid="pone.0005689-Baeuerle1">&#x0005b;4&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005689-Perkins1">&#x0005b;6&#x0005d;</xref>. Under basal conditions NF-&#x003ba;B is bound in the cell cytoplasm to I&#x003ba;B, a group &#x0005b;NFKBIA (I&#x003ba;B&#x003b1;), NFKBIB (I&#x003ba;B&#x003b2;), and NFKBIE (I&#x003ba;B&#x003b5;) are the key members) of NF-&#x003ba;B sensitive proteins that limits NF-&#x003ba;B nuclear translocation and inhibits its ability to bind the promoter region of sensitive genes <xref ref-type="bibr" rid="pone.0005689-Perkins1">&#x0005b;6&#x0005d;</xref>. NF-&#x003ba;B activation can occur in several pathways: most commonly, it is triggered in a canonical manner in response to inflammatory cytokines (such as TNF&#x003b1;), engagement of T cell receptor, or lypopolysaccharide (LPS) that induces rapid phosphorylation, at Ser32 and Ser36 residues, of I&#x003ba;B by the I&#x003ba;B kinase complex &#x0005b;consisting of the catalytic subunits CHUK (IKK&#x003b1;) and IKBKB (IKK&#x003b2;)&#x0005d; and several copies of the regulatory subunit called NF-&#x003ba;B essential modifier. Phosphorylated I&#x003ba;B&#x003b1; undergoes ubiquitin-induced degradation by the 26S proteosome and allows the nuclear translocation of the NF-&#x003ba;B, NFKB1-RELA dimers <xref ref-type="bibr" rid="pone.0005689-Baeuerle1">&#x0005b;4&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005689-Perkins1">&#x0005b;6&#x0005d;</xref>. A subset of NF-&#x003ba;B activating stimuli such as stimulation of CD40 activate the non-canonical, or alternative, pathway in which activation of catalytic subunits CHUK results in the formation of NFKB2 (p52) from p100 and the generation of NFKB2-RELB heterodimers that target distinct &#x003ba;B elements <xref ref-type="bibr" rid="pone.0005689-Baeuerle1">&#x0005b;4&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005689-Perkins1">&#x0005b;6&#x0005d;</xref>. Activation of this alternative pathway of NF-&#x003ba;B is not associated with formation of NFKB1 (p50) dimers <xref ref-type="bibr" rid="pone.0005689-Perkins1">&#x0005b;6&#x0005d;</xref>.</p><p>Following inhalation into the lower respiratory tract silica particles interact with epithelial cells and macrophages inducing NF-&#x003ba;B activation <xref ref-type="bibr" rid="pone.0005689-Chen1">&#x0005b;7&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005689-Kang1">&#x0005b;9&#x0005d;</xref>. Binding of NF-&#x003ba;B to DNA promotes the transcription of genes involved in mediating the inflammatory (TNF&#x003b1;) and fibrotic (collagens) responses to silica in mice <xref ref-type="bibr" rid="pone.0005689-Hubbard1">&#x0005b;10&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005689-Ortiz1">&#x0005b;12&#x0005d;</xref>. Because of the potential importance of NF-&#x003ba;B in the pathogenesis of silicosis, this transcription factor has been considered a primary target to antagonize silica-induced inflammation in the lung <xref ref-type="bibr" rid="pone.0005689-Hubbard1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Porter1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Sacks1">&#x0005b;13&#x0005d;</xref>. However, the long-term biologic effects of inhibiting NF-&#x003ba;B in vivo in response to silica are unknown.</p><p>Due to the lack of treatment for silicosis, lung transplantation is considered the only a therapeutic alternative. In the present work we characterized the outcome of patients that received lung transplantation for the treatment of their silica-induced respiratory failure. We also treated silica exposed C57BL/6 mice with a pharmacologic inhibitor (BAY 11-7085) of NFKBIA (I&#x003ba;B&#x003b1;) phosphorylation <xref ref-type="bibr" rid="pone.0005689-Pierce1">&#x0005b;14&#x0005d;</xref> or exposed transgenic mice expressing a dominant negative NFKBIA (I&#x003ba;B&#x003b1;) mutant protein <xref ref-type="bibr" rid="pone.0005689-Brockman1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Skerrett1">&#x0005b;16&#x0005d;</xref> under the control of epithelial specific promoters mice to silica to determine whether the systemic or epithelial inhibition of NF-&#x003ba;B activation is a valid therapeutic approach in silicosis.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study population</title><p>The University of Pittsburgh Institutional Review Board approved the procedures used in this study and information was minimized to comply with HIPPA regulations. We identified 990 patients that received lung transplantation at the University of Pittsburgh during the period of May 1986 to July 2007. From this database we selected patients that received lung transplantation for the diagnosis of silicosis (n&#x0200a;&#x0003d;&#x0200a;13) and assessed the overall survival and rate of graft rejection, by measuring the development of bronchiolitis obliterans (BO). We compared the rate of rejection to that of patients with idiopathic pulmonary fibrosis (IPF) that was selected as a control group because survival benefit of lung transplantation has been identified for these patients <xref ref-type="bibr" rid="pone.0005689-Thalbut1">&#x0005b;17&#x0005d;</xref>. Inclusion criteria for IPF included histological evidence of usual interstitial pneumonia (UIP) in the explanted lungs and fulfilled the criteria established by the American Thoracic Society and European Respiratory Society <xref ref-type="bibr" rid="pone.0005689-1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-2">&#x0005b;19&#x0005d;</xref>. Diagnosis of silicosis or UIP was unequivocally established by blind re-evaluation (S.Yousem). Upon further evaluation of explanted lungs, two of the twelve patients with diagnosis of silicosis demonstrated evidence of coexistent pneumoconiosis or Kaplan syndrome and were withdrawn for further analysis. Characterization of the TNF&#x003b1; expression and the NF-&#x003ba;B activation was conducted by immunohistochemistry in paraffin-embedded lung tissues (4 &#x000b5;m) isolated from silicosis patients at time of lung transplantation.</p></sec><sec id="s2b"><title>Silica and BAY 11-7085 Treatment</title><p>All procedures were approval by the Institutional Animal Care and Use Committee of the University of Pittsburgh. Specific pathogen-free female C57BL/6 (Charles River laboratories, Kingston, NY), and mice genetically deficient in both (p55p75&#x02212;/&#x02212;) TNF receptors (The Jackson Laboratory, Bar Harbor, ME) weighing 20 to 25 grams were housed in pathogen-free cabinets as previously described <xref ref-type="bibr" rid="pone.0005689-Ortiz1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Ortiz2">&#x0005b;20&#x0005d;</xref>. Animals were exposed to silica (0.2 g/kg) or saline (control) as previously described <xref ref-type="bibr" rid="pone.0005689-Ortiz1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Ortiz2">&#x0005b;20&#x0005d;</xref> and killed at selected times (3, 7, 14, and 28 d) after silica exposure. Prior to exposure, crystalline silica (&#x003b1;-quartz, average diameter: 1.7 &#x000b5;m, U.S. Silica Co., Berkeley Springs, WV) was sterilized (200&#x000b0;C, 16 h) to inactivate endotoxin contamination. Silica suspension in sterile 0.9&#x00025; NaCl (Baxter Healthcare Corp., Deerfield, IL) was prepared by sonicating immediately prior to intratracheal instillation <xref ref-type="bibr" rid="pone.0005689-Ortiz1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Ortiz2">&#x0005b;20&#x0005d;</xref>. Groups of mice received 10 mg of BAY 11-7085 (BIOMOL International L.P. Plymouth Meeting, PA)/Kg body weight/day/28 d by i.p. injection in 180 &#x000b5;l of vehicle (0.5&#x00025; (w/v) methylcellulose in water) or vehicle alone (control). Mice were anesthetized with sodium pentobarbital (200 mg/kg i.p., Henry Schein, Indianapolis, IN) followed by exsanguination via severing of the posterior abdominal aorta. All the lung samples were harvested at a terminal anesthesia point, snap frozen in liquid nitrogen, and stored at &#x02212;80&#x000b0;C for RNA or hydroxyproline content analysis. Lung hydroxyproline was determined according to the method of Kivirikko et al. as previously described <xref ref-type="bibr" rid="pone.0005689-Ortiz1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Ortiz2">&#x0005b;20&#x0005d;</xref>.</p></sec><sec id="s2c"><title>Generation of CCSP and SPC-dnI&#x003ba;B&#x003b1; transgenic mice</title><p>To inhibit NFKBIA (I&#x003ba;B&#x003b1;) in the airway epithelium, a CCSP-dnI&#x003ba;B&#x003b1; construct was generated by cloning a dominant-negative (dn) I&#x003ba;B mutant <xref ref-type="bibr" rid="pone.0005689-Brockman1">&#x0005b;15&#x0005d;</xref> under the regulation of rat Clara cell secretory protein (CCSP) promoter <xref ref-type="bibr" rid="pone.0005689-Hoyle1">&#x0005b;21&#x0005d;</xref>. Details of the generation of the CCSP-dnI&#x003ba;B&#x003b1; mice are included in the supplemental information (<xref ref-type="supplementary-material" rid="pone.0005689.s006">Method S1</xref>). In addition, transgenic SPC-dnI&#x003ba;B&#x003b1; mice (kind gift of Christopher Wilson) were generated at the University of Washington and have dnI&#x003ba;B&#x003b1; under the regulation of the human SPC (SFTPC) promoter as previously described <xref ref-type="bibr" rid="pone.0005689-Skerrett1">&#x0005b;16&#x0005d;</xref>. CCSP- and SPC-dnI&#x003ba;B&#x003b1; mice were crossed with C57BL/6 strain mice for a minimum of 7 generations before used in experiments. Transgene negative littermates were used as controls. Mice were housed under specific-pathogen free conditions in filtered-air cages, and permitted unlimited access to sterile food and water.</p></sec><sec id="s2d"><title>Morphology and Morphometry</title><p>Inflammatory cell infiltration was determined by morphometric assessment (conducted blindly by G. Lungarella) and expressed as percentage volume-densities of fibrosis &#x0005b;Vv(f)&#x0005d; was measured according to the stereological principle of Glagoleff and Weibel as previously described <xref ref-type="bibr" rid="pone.0005689-Cavarra1">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Gambelli1">&#x0005b;23&#x0005d;</xref>. Point counting was performed at a magnification of &#x000d7;100, by determining 20 random fields per slide and using a multipurpose grid to count 45 points/field to a total of 900 points/specimen. This method measures inflammatory cell infiltration within alveolar septae and alveolar spaces with deposition of extracellular matrix.</p></sec><sec id="s2e"><title>Quantitative real-time polymerase chain reaction (qRT-PCR) assay</title><p>To adequately cover the TNF&#x003b1; and NF-&#x003ba;B pathway and targeted cytokines, 40 transcripts selected were analyzed by qRT-PCR. Total RNA was isolated with TRIzol reagent (Invitrogen, Carlsbad, CA) and quantity was assessed by absorbance (NanoDrop, Thermo Scientific, Pittsburgh, PA). RNA (100 ng) was reverse transcribed (High Capacity cDNA Archive Kit, Applied Biosystems Inc., Foster City, CA) and cDNA was PCR amplified with primers and TaqMan Universal PCR Master Mix (Applied Biosystems). Arranged into functional groups, primers (SABiosciences, Frederick, MD) included: <italic>A. TNF pathway group</italic> (19 transcripts): TNF, TNFSF10, TNFSF14, TNFRSF1A, TNFRSF1B, TNFRSF10B, CD27, CD40, LTBR, TNFAIP3, TRAF2, TRAF3, TRADD, TBK1, FADD, CFLAR, RIPK1, RIPK2, and MAP3K1, <italic>B. NFKB pathway group</italic> (9 transcripts): NFKB1, NFKB2. IKBKB, IKBKE, IKBKG, REL, RELA, RELB, and CHUK, and <italic>C. Cytokine group</italic> (12 transcripts mRNAs): CCL2, IL1B, IL6, CSF2, CSF3, IFNG, IRAK1, IRAK2, NLRP2, KAT2B, STAT1, and EGR1 (All abbreviations are current Entrez Gene official symbols and official full names are presented in <xref ref-type="supplementary-material" rid="pone.0005689.s005">Table S1</xref>). Analysis was performed with an Applied Biosystems 7900HT System (95&#x000b0;C 10 min; 40 cycles 95&#x000b0;C, 15 s; 60&#x000b0;C, 1 min). The expression of each transcript relative to Heat shock protein 90 kDa alpha (cytosolic), class B member 1 (HSP90AB1) transcript level was determined using the 2<sup>&#x02212;&#x00394;&#x00394;C</sup>T method <xref ref-type="bibr" rid="pone.0005689-1">&#x0005b;18&#x0005d;</xref> and normalized to strain-matched mice exposed to saline.</p></sec><sec id="s2f"><title>Northern Analysis and Ribonuclease Protected Assays</title><p>Analysis of the expression of collagen, type I, alpha 1 (COL1&#x003b1;1), TNF&#x003b1;, and RPS18 (18S) mRNA was conducted as previously described <xref ref-type="bibr" rid="pone.0005689-Ortiz1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Ortiz2">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Gambelli1">&#x0005b;23&#x0005d;</xref>. Metalloproteinase 2 (MMP2), and tissue inhibitor of metalloproteinase 1 (TIMP1) transcript levels were determined by a ribonuclease protection assay (RiboQuant&#x02122;, Becton, Dickinson and Company, Franklin Lakes, NJ).</p></sec><sec id="s2g"><title>Isolation of Clara and Alveolar Epithelial type II (AEII) cells, and electrophoretic mobility Shift Assay (EMSA), and Western Blot assays</title><p>Clara and AEII cells were isolated from the lung of transgenic and wild-type mice as previously described <xref ref-type="bibr" rid="pone.0005689-Corti1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Warshamana1">&#x0005b;25&#x0005d;</xref>. Complete description of the isolation protocol is included in supplemental data (<xref ref-type="supplementary-material" rid="pone.0005689.s006">Methods S1</xref>). Nuclear extracts from Clara cells, AEII cells, or the lungs of silica-treated mice were prepared as previously described <xref ref-type="bibr" rid="pone.0005689-Gambelli1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Gozal1">&#x0005b;26&#x0005d;</xref>. Complete description of the EMSA protocol is included in supplemental data. I&#x003ba;B expression was studied by proving proteins with an affinity purified rabbit polyclonal antibodies specific to total or phospho-I&#x003ba;B &#x0005b;PhosphoPlus I&#x003ba;B -alpha (Ser<sup>32</sup>) antibody kit, New England Biolabs, Ipswich, MA&#x0005d;.</p></sec><sec id="s2h"><title>Quantification of apoptosis in lung tissues by Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)</title><p>Apoptotic cells in lung tissues from mice treated with silica or silica plus Bay 11-7085 (n&#x0200a;&#x0003d;&#x0200a;5 mice/group) was performed using a TUNEL assay (Travigen Laboratories, Gaithersburg, MD). The mean of the numbers of TUNEL-positive cells was determined using 3 sections/mouse (&#x000d7;400 light microscopy) as previously described <xref ref-type="bibr" rid="pone.0005689-Kuwano1">&#x0005b;27&#x0005d;</xref>.</p></sec><sec id="s2i"><title>Statistics</title><p>We analyzed both overall survival and rejection-free survival, using the date of transplant as the start date of follow-up. Survival curves were computed using the Kaplan-Meier method. Differences in survival according to primary diagnosis were assessed using the logrank test and the Cox proportional hazards model. Differences between murine strains were analyzed using ANOVA with Fisher's PLSD test for pair-wise comparison (statview 4; Abacus Concept, INC., Berkeley, CA). The differences in transcript levels are expressed as fold change of silica-treated mice compared to saline exposed mice and significant differences were determined by One-way Analysis of Variance with Holm-Sidak all pairwise multiple comparison procedure. Values are expressed as mean&#x000b1;SEM, and p value&#x0003c;0.05 was considered significant.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Patients with silicosis have poor prognosis following lung transplantation</title><p>Characteristics of the patients with silicosis and IPF are described in <xref ref-type="table" rid="pone-0005689-t001">Table 1</xref>. We analyzed both overall and rejection-free survival of patients with silicosis or IPF, using the transplant date as the start of follow-up. Ten of the 11 patients with silicosis (average age 52.4&#x000b1;8.6 yr) received single lung transplantation (SLT) and 1 received a double lung transplant (DLT). Of the 79 patients with IPF (average age 54.0&#x000b1;9.9 yr), 71 patients received SLT and 8 patients received DLT. Survival at 30-, 60-, or 90-d did not differ between the two groups as assessed by the Kaplan-Meier method. Differences in survival according to primary diagnosis also were assessed using the log-rank test and the Cox proportional hazards model. Median survival of silicosis patients (2.4 yr, <xref ref-type="fig" rid="pone-0005689-g001">Figure 1A</xref>) was somewhat less than that of IPF patients (5.3 yr; lower confidence bounds 0.2: 2.8 yr; p&#x0200a;&#x0003d;&#x0200a;0.07 by the logrank test; <xref ref-type="fig" rid="pone-0005689-g001">Figure 1A</xref>). This analysis is confounded by gender (i.e., no female silicosis patients) as survival differed between sexes for IPF patients. Thus, female IPF patients were transplanted at a significantly younger age (51.5&#x000b1;9 years) than their male counterpart (55.9&#x000b1;10.2 yr) and demonstrated a significant (p&#x0003c;0.005) survival difference (11.6 yr) when compared to male patients with IPF (3.5 yr). All 11 patients who received lung transplantation for silicosis died during the follow up, while only 37 deaths occurred among the 79 patients with IPF during follow-up. Transplantation type, SLT versus DLT, did not affect survival outcome.</p><fig id="pone-0005689-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005689.g001</object-id><label>Figure 1</label><caption><title>Patients with silicosis have poor outcome following lung transplantation.</title><p><xref ref-type="fig" rid="pone-0005689-g001">Figure 1</xref> illustrates the survival rates (1A) and the rejection free time (1B) for patients with idiopathic pulmonary fibrosis (IPF; n&#x0200a;&#x0003d;&#x0200a;79) or silicosis (n&#x0200a;&#x0003d;&#x0200a;11) following lung transplantation. Survival curves were computed using the Kaplan-Meier method. Differences in survival according to primary diagnosis were assessed using the logrank test and the Cox proportional hazards model as described in the text.</p></caption><graphic xlink:href="pone.0005689.g001"/></fig><table-wrap id="pone-0005689-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005689.t001</object-id><label>Table 1</label><caption><title>Patient Characteristics.</title></caption><graphic id="pone-0005689-t001-1" xlink:href="pone.0005689.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005689-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IPF</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;&#x0003d;&#x0200a;79)</td><td align="left" rowspan="1" colspan="1">Silicosis</td><td align="left" rowspan="1" colspan="1">(n&#x0200a;&#x0003d;&#x0200a;11)</td><td align="left" rowspan="1" colspan="1">(p-value)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No. of Patients</td><td align="left" rowspan="1" colspan="1">&#x00025;</td><td align="left" rowspan="1" colspan="1">No. of Patients</td><td align="left" rowspan="1" colspan="1">&#x00025;</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td colspan="6" align="left" rowspan="1"><bold>Sex</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Male</bold></td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">67.1</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">100.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Female</bold></td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">32.9</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">(p&#x0200a;&#x0003d;&#x0200a;0.03)</td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Race</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Caucasian</bold></td><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">92.4</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">100.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>African-American</bold></td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">6.3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Hispanic</bold></td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.0</td><td align="left" rowspan="1" colspan="1">(p&#x0200a;&#x0003d;&#x0200a;1.0)</td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Age at Transplant (years)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Mean</bold></td><td align="left" rowspan="1" colspan="1">54.5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">52.4</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>SD</bold></td><td align="left" rowspan="1" colspan="1">10.3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">8.6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>N</bold></td><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(p&#x0200a;&#x0003d;&#x0200a;0.31)</td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Pre-transplant FVC (L)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Mean</bold></td><td align="left" rowspan="1" colspan="1">1.9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>SD</bold></td><td align="left" rowspan="1" colspan="1">0.69</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>N</bold></td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(p&#x0200a;&#x0003d;&#x0200a;0.76)</td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Pre-transplant 6MWD (m)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Mean</bold></td><td align="left" rowspan="1" colspan="1">1157.0</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">993.2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>SD</bold></td><td align="left" rowspan="1" colspan="1">293.6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">300.3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>N</bold></td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(p&#x0200a;&#x0003d;&#x0200a;0.13)</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label/><p>P-value denotes the statistical difference between Patients with IPF and those with silicosis.</p></fn></table-wrap-foot></table-wrap><p>Rejection of the transplanted lung was defined as the development of bronchiolitis obliterans syndrome (BOS). BOS was defined by an irreversible (&#x02265;20&#x00025;) decrease in forced expiratory volume in one second (FEV1) using each patients' best post transplant FEV1 after lung transplant as baseline, and the development of obliterative bronchiolitis (OB) in lung biopsy of the transplanted lung <xref ref-type="bibr" rid="pone.0005689-Estenne1">&#x0005b;28&#x0005d;</xref>. The rate of graft rejection increased in silicosis patients (<xref ref-type="fig" rid="pone-0005689-g001">Figure 1B</xref>) as compared to IPF patients (p&#x0003c;0.05, by the logrank test). Median graft survival was 0.9 and 2.4 yr, respectively, for the silicosis and IPF groups. A lower confidence bound for the silicosis group was 0.22 yr; a 95&#x00025; confidence interval for the IPF group was 1.5: 3.6 yr.</p></sec><sec id="s3b"><title>Enhanced macrophage TNF&#x003b1; expression and epithelial NF-&#x003ba;B activation in silicosis</title><p>TNF&#x003b1; expression and NF-&#x003ba;B activation was determined by performing immune staining in paraffin embedded sections of lung tissues isolated from the lungs of subjects afflicted with silicosis at the time of lung transplantation. In all 11 silicosis patients, large areas of the lung parenchyma were replaced by coalescence of silicotic nodules (<xref ref-type="fig" rid="pone-0005689-g002">Figure 2A</xref>). These nodules contain fibrinous material, had few cells, and did not demonstrate TNF&#x003b1; immunostaining (<xref ref-type="fig" rid="pone-0005689-g002">Figure 2A</xref>). In contrast, TNF&#x003b1; immunostaining was evident in preserved regions of the lung parenchyma adjacent to the silicotic nodules, which was confined to primarily to macrophages (<xref ref-type="fig" rid="pone-0005689-g002">Figure 2B</xref>), and was particularly strong in macrophages that exhibit excessive silica particles in phagosomes (<xref ref-type="supplementary-material" rid="pone.0005689.s001">Figure S1</xref>). Immunostaining for NF-&#x003ba;B activation was predominantly detected in the nuclei of epithelial cells adjacent to TNF&#x003b1; immunostaining macrophages (<xref ref-type="supplementary-material" rid="pone.0005689.s002">Figure S2</xref>).</p><fig id="pone-0005689-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005689.g002</object-id><label>Figure 2</label><caption><title>TNF&#x003b1; expression in silicotic lung is predominantly identified in macrophages.</title><p>Panel A show low photomicrograph (&#x000d7;200) of lung tissue isolated from a silica exposed subject at the time of lung transplantation. Lung parenchyma is replaced by silicotic nodule characterized by a dense palisade of fibroblast surrounding a central fibrinous core that is devoided of cells and abuts the distal airway. Alveolar macrophages accumulate in relatively normal alveolar areas adjacent to the silicotic nodule (circle). Panel B show high (&#x000d7;400) magnification of the area identified in panel A, illustrating immunochemistry signal with anti-TNF&#x003b1; antibody that is confined to cells with macrophage morphology.</p></caption><graphic xlink:href="pone.0005689.g002"/></fig></sec><sec id="s3c"><title>Lung Transcripts for TNF&#x003b1;, NF-&#x003ba;B, and cytokines increased in silica-treated mice</title><p>To ascertain whether TNF&#x003b1; or NF-&#x003ba;B signaling pathways and targeted cytokines were altered in silica treated mice, 40 lung transcripts were assessed in the lung of C57BL/6 mice at 3, 7, 14 and 28 d after silica exposure. Overall, 26 transcripts increased (p&#x0003c;0.05) within 3 d and were slightly higher than the mean level at 7 d (<xref ref-type="fig" rid="pone-0005689-g003">Figure 3A</xref> and <xref ref-type="fig" rid="pone-0005689-g003">Figure 3B</xref>). At 28 d, 38 of the 40 transcripts were increased (only CHUK and EGR1 were not significantly increased). Of the 40 transcripts measured, TNF&#x003b1; increased the most (&#x0223c;90-fold). TNF&#x003b1; receptors, TNFRSF1B and TNFRSF1A, increased, as did transcripts that are rapidly induced by TNF&#x003b1;, TNFAIP3 and RIPK2 (<xref ref-type="fig" rid="pone-0005689-g003">Figure 3C</xref>). All 19 TNF signaling pathway transcripts increased by 28 d (<xref ref-type="fig" rid="pone-0005689-g003">Figure 3A</xref>). Albeit somewhat less the TNF signaling pathway, NF-&#x003ba;B signaling pathway transcripts also increased in mouse lung following silica exposure. At 28 d, NFKB1 (p50) increased &#x0223c;5&#x02013;10 fold and Rel/NFKB family transcription factors (REL, RELA, RELB) increased &#x0223c;5&#x02013;15 fold (<xref ref-type="fig" rid="pone-0005689-g003">Figure 3C</xref>). Only 1 (CHUK) of 9 transcripts in the NF-&#x003ba;B signaling pathway was not significantly different from control by 28 d. In addition, 11 of 12 cytokine transcripts increased significantly with the progression of treatment. Of these, cytokine controlling the production, differentiation, and function of monocytes/macrophages (CCL2 a.k.a. MCP1, and CSF2 a.k.a. GM-CSF), and of granulocytes (CSF2: a.k.a. G-CSF; CCL2) are noteworthy (<xref ref-type="fig" rid="pone-0005689-g003">Figure 3C</xref>). In addition, transcripts encoding interleukins (IL1B, IL6), IFNG, and the downstream transcription activator, STAT1, increased markedly (&#x0223c;8&#x02013;20 fold at 28 d).</p><fig id="pone-0005689-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005689.g003</object-id><label>Figure 3</label><caption><title>Tumor necrosis factor alpha (TNF&#x003b1;), nuclear factor kappa B (NFKB) and associated cytokines increased in mouse lung following silica treatment.</title><p>Mice (n&#x0200a;&#x0003d;&#x0200a;5 C57BL/6J mice/group) were treated with silica, lung mRNA was obtained at 3, 7, 14, and 28 days, and 40 transcript levels were assessed by qRT-PCR. (A) Self-organizing map visualization of transcripts in Tree View. The order of the transcripts is greatest (top) to lowest (bottom) as measured on day 28. (B) Visualization of Mean Tendency of the 40 transcripts measured. Values are mean&#x000b1;standard error and &#x0002a;p&#x0003c;0.05 as determined by One way analysis of variance with all pairwise multiple comparison procedures (Holm-Sidak method). (C) Transcript levels of selected members of TNF&#x003b1; signaling, NFKB signaling, and downstream cytokine families. All abbreviations are current Entrez Gene official symbols and official full names are presented in <xref ref-type="supplementary-material" rid="pone.0005689.s005">Table S1</xref>.</p></caption><graphic xlink:href="pone.0005689.g003"/></fig></sec><sec id="s3d"><title>TNF&#x003b1; receptors mediate NF-&#x003ba;B activation in experimental silicosis</title><p>We have previously reported that TNF&#x003b1; receptors play a fundamental role in experimental silicosis and TNF&#x003b1; receptor deficient mice are protected from silica-induced lung fibrosis <xref ref-type="bibr" rid="pone.0005689-Ortiz1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Ortiz2">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Hoyle1">&#x0005b;21&#x0005d;</xref>. Here we show that TNF&#x003b1;-receptor mediated signaling is an important determinant of the NF-&#x003ba;B activation in the mouse lung in response to silica. Instillation of silica particles increased phophorylated I&#x003ba;B moiety (<xref ref-type="fig" rid="pone-0005689-g004">Figure 4</xref>). This increase was followed by I&#x003ba;B rapid degradation and eventual disappearance of (total I&#x003ba;B) in the lungs of silica-sensitive C57BL/6 mice. In contrast to C57BL/6 mice, these changes in I&#x003ba;B did not take place in the lungs of double (p55p75) TNF&#x003b1; receptor deficient mice developed in the same silica-sensitive C57BL/6 genetic background. Silica-induced degradation of phospho I&#x003ba;B is associated with NF-&#x003ba;B activation in the lungs of C57BL/6 (<xref ref-type="fig" rid="pone-0005689-g004">Figure 4</xref>). Analysis of NF-&#x003ba;B gel shift in lung nuclear extracts show that silica induces two bands: a lower band representing the p50-p50 (NFKB1-NFKB1) homodimer, present in both the C57BL/6 and the double (p55p75&#x02212;/&#x02212;) TNF&#x003b1; receptor deficient mice, and an upper band, only observed in the lungs of C57BL/6 mice, representing the p50-p65 (NFKB1:RELA) heterodimer (<xref ref-type="fig" rid="pone-0005689-g004">Figure 4</xref>). Supershift assays confirmed that the lower band could be competed by excess cold, but not by mutant, probe while the upper band could be displaced by incubation of the nuclear extract with an antibody against the p50 or the p65 complex (<xref ref-type="fig" rid="pone-0005689-g004">Figure 4</xref>). These data indicate that silica induces a canonical, TNF&#x003b1; receptor-mediated, activation of NF-&#x003ba;B in the mouse lung.</p><fig id="pone-0005689-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005689.g004</object-id><label>Figure 4</label><caption><title>TNF&#x003b1; receptors mediate NF-&#x003ba;B activation in experimental silicosis.</title><p>Western blot (upper panel) representing expression of total and phosphorylated I&#x003ba;B (phospho I&#x003ba;B) in the lungs of silica-sensitive C57BL/6, or double (p55/p75&#x02212;/&#x02212;) TNF&#x003b1; receptor deficient mice following the intratracheal instillation of silica particles as described in the text. Lower panel illustrates the DNA binding activity of NF-&#x003ba;B in crude nuclear extracts from whole lung isolated from C57BL/6, and double (p55/p75&#x02212;/&#x02212;) TNF&#x003b1; receptor deficient mice after silica exposure. Silica induces two bands: a lower band representing the p50-p50 homo-dimer, present in both the C57BL/6 and the double (p55p75&#x02212;/&#x02212;) TNF&#x003b1; receptor deficient mice, and an upper band, only observed in the lungs of C57BL/6 mice, representing the p50-p60 heterodimer. Excess probe represents NF-&#x003ba;B binding in lung nuclear extract of a silica-treated mouse, assayed in the presence of excess unlabelled oligonucleotide as a competitor. Competition assays were performed using 400 times excess of unlabeled probe or NF-&#x003ba;B mutant oligonucleotide (Santa Cruz). Supershifts were performed by adding to the binding mixture antibodies to p50 (sc1190X) or to p65 (sc372X) or against C-Jun/AP-1 (sc44X) (Santa Cruz) before adding the labeled probe to the mixture.</p></caption><graphic xlink:href="pone.0005689.g004"/></fig><p>Following the early activation of NF-&#x003ba;B, lung I&#x003ba;B mRNA increased in silica-exposed C57BL/6 mice (not shown) and I&#x003ba;B protein returned to baseline (<xref ref-type="fig" rid="pone-0005689-g004">Figure 4</xref>). Enhanced NF-&#x003ba;B activation was appreciated in the lungs of silica-exposed C57BL/6 mice for the entire duration of the experiments, and it was readily demonstrated 14 and 28 d after silica exposure (<xref ref-type="fig" rid="pone-0005689-g005">Figure 5</xref>). Therefore, it is conceivable that inhibition of NF-&#x003ba;B activity could in turn modulate expression of NF-&#x003ba;B sensitive genes and alters the development of silica-induced lung injury in these mice.</p><fig id="pone-0005689-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005689.g005</object-id><label>Figure 5</label><caption><title>Systemic inhibition of NF-&#x003ba;B activity ameliorates silica-induced lung injury in mice.</title><p>A) DNA binding activity of NF-&#x003ba;B in crude nuclear extracts from whole lung isolated from C57BL/6 mice 14 and 28 days after silica, or silica&#x0002b;BAY exposure. Excess probe represents NF-&#x003ba;B binding in lung nuclear extract of a silica-treated mouse, assayed in the presence of excess unlabelled oligonucleotide as a competitor. Antibody supershifts were performed using the nuclear extract of a C57BL/6 silica-treated mouse as described in <xref ref-type="sec" rid="s2">Methods</xref> section. B) Northern blot analysis of TNF&#x003b1;, &#x003b1;1(I) collagen, and 18S (loading control) mRNA expression in mouse lung 14 days following the intratracheal injection of saline as control, silica alone, or silica&#x0002b;BAY as described in <xref ref-type="sec" rid="s2">Methods</xref> section. C) The effect of BAY on metalloproteinase (MMPs) RNA expression in mouse lung following silica exposure. Total lung RNA was isolated from the lungs of C57BL/6 mice 14 days after control, silica, or silica&#x0002b;BAY and subjected to RPA as described in <xref ref-type="sec" rid="s2">Methods</xref> section. D) The panels show low (&#x000d7;100) power magnification photomicrographs of the lung obtained from lung tissues of C57BL/6 mice exposed to saline as control (A), silica (B), or silica&#x0002b;BAY (C) as described in the <xref ref-type="sec" rid="s2">Methods</xref> section. TB&#x0200a;&#x0003d;&#x0200a;terminal bronchiole. Bar&#x0200a;&#x0003d;&#x0200a;20 &#x000b5;m. Gel illustrations are representative of 4 different experiments.</p></caption><graphic xlink:href="pone.0005689.g005"/></fig></sec><sec id="s3e"><title>Systemic inhibition of NF-&#x003ba;B activity ameliorates silica-induced lung injury in mice</title><p>To investigate whether inhibiting systemic or lung epithelial cell-specific NF-&#x003ba;B activation is protective in the development of experimental silicosis we adopted two experimental approaches. Systemic inhibition of NF-&#x003ba;B activation was accomplished using a novel pharmacologic agent, BAY-117821, which irreversibly inhibits TNF&#x003b1;-induced phosphorylation of I&#x003ba;B in human endothelial cells, and NF-&#x003ba;B activation in silica stimulated macrophages <xref ref-type="bibr" rid="pone.0005689-Pierce1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Gambelli1">&#x0005b;23&#x0005d;</xref>. In preliminary studies, dose responses (2.5&#x02013;50 mg/kg) were tested and 10 mg/kg bwt/d (180 &#x000b5;l 0.5&#x00025; (w/v) methylcellulose i.p.) was capable of consistently inhibiting the silica-induced activation of NF-&#x003ba;B in multiple organs including the lungs of C57BL/6 mice without apparent toxicity to the mice (<xref ref-type="fig" rid="pone-0005689-g005">Figure 5</xref>).</p><p>Silica treatment induced NF-&#x003ba;B activation, 14 and 28 d, in the lungs of C57BL/6 mice (<xref ref-type="fig" rid="pone-0005689-g005">Figure 5A</xref>). Activation of NF-&#x003ba;B was associated with increased inflammatory (TNF&#x003b1;), fibrotic (COL1A1), and metalloproteinases (MMPs) transcripts in the lungs of silica-exposed C57BL/6 mice (<xref ref-type="table" rid="pone-0005689-t002">Table 2</xref>, <xref ref-type="fig" rid="pone-0005689-g003">Figure 3C</xref>, <xref ref-type="fig" rid="pone-0005689-g005">Figure 5B&#x00026;C</xref>, and <xref ref-type="supplementary-material" rid="pone.0005689.s003">Figure S3</xref>). Compared to control-treated mice, silica-exposed C57BL/6 mice developed fibrosis with increased percentage of fibrosis &#x0005b;(Vv(f)&#x0005d; (<xref ref-type="table" rid="pone-0005689-t002">Table 2</xref>, <xref ref-type="fig" rid="pone-0005689-g005">Figure 5D</xref>), lung hydroxyproline (<xref ref-type="table" rid="pone-0005689-t002">Table 2</xref>), and apoptotic cells, identified as TUNEL positive cells (<xref ref-type="supplementary-material" rid="pone.0005689.s004">Figure S4</xref>, and <xref ref-type="table" rid="pone-0005689-t003">Table 3</xref>). Treatment of silica-exposed C57BL/6 mice with BAY 11-7085 compound inhibited the lung NF-&#x003ba;B activation (<xref ref-type="fig" rid="pone-0005689-g005">Figure 5A</xref>), inflammatory and fibrotic transcripts (<xref ref-type="table" rid="pone-0005689-t002">Table 2</xref>, <xref ref-type="fig" rid="pone-0005689-g005">Figure 5B&#x00026;C</xref>, and <xref ref-type="supplementary-material" rid="pone.0005689.s003">Figures S3</xref>), and histological evidence of inflammatory infiltrates, fibrotic lesions (<xref ref-type="fig" rid="pone-0005689-g005">Figure 5D</xref>, <xref ref-type="table" rid="pone-0005689-t002">Table 2</xref>), and TUNEL positive cells (<xref ref-type="table" rid="pone-0005689-t003">Table 3</xref>).</p><table-wrap id="pone-0005689-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005689.t002</object-id><label>Table 2</label><caption><title>The effect of BAY Treatment on Silica Induced Gene Expression.</title></caption><graphic id="pone-0005689-t002-2" xlink:href="pone.0005689.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005689-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Treatment Condition</td><td align="left" rowspan="1" colspan="1">TNF&#x003b1;</td><td align="left" rowspan="1" colspan="1">&#x003b1;1(I) Collagen</td><td align="left" rowspan="1" colspan="1">TIMP-1</td><td align="left" rowspan="1" colspan="1">MMP1</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>C57BL/6 Control</bold></td><td align="left" rowspan="1" colspan="1">0.164&#x000b1;0.004</td><td align="left" rowspan="1" colspan="1">0.310&#x000b1;0.014</td><td align="left" rowspan="1" colspan="1">0.079&#x000b1;0.06</td><td align="left" rowspan="1" colspan="1">0.014&#x000b1;0.004</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C57BL/6 silica</bold></td><td align="left" rowspan="1" colspan="1">0.215&#x000b1;0.006<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">0.440&#x000b1;0.019<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">0.10&#x000b1;0.010 <xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">0.020&#x000b1;0.007<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C57BL/6 Silica&#x0002b;BAY</bold></td><td align="left" rowspan="1" colspan="1">0.172&#x000b1;0.005<xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">0.340&#x000b1;0.007<xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">0.088&#x000b1;0.013<xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">0.014&#x000b1;0.002<xref ref-type="table-fn" rid="nt103">&#x02020;</xref></td></tr></tbody></table><table-wrap-foot><fn id="nt102"><label>&#x0002a;</label><p>Statistically significant different when compared to control-treated mice.</p></fn><fn id="nt103"><label>&#x02020;</label><p>Statistically significant different when compared to silica exposed mice.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0005689-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005689.t003</object-id><label>Table 3</label><caption><title>The effect of BAY Treatment on Silica Induced Lung Injury.</title></caption><graphic id="pone-0005689-t003-3" xlink:href="pone.0005689.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005689-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Treatment Condition n&#x0200a;&#x0003d;&#x0200a;6 mice/group</td><td align="left" rowspan="1" colspan="1">Hydroxyproline (&#x000b5;g/Left Lung)</td><td align="left" rowspan="1" colspan="1">Volume-Density Fibrosis Vv (&#x00025;f)</td><td align="left" rowspan="1" colspan="1">TUNEL-Positive cells (per mm<sup>2</sup>)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>C57BL/6 Control</bold></td><td align="left" rowspan="1" colspan="1">46&#x000b1;5</td><td align="left" rowspan="1" colspan="1">1&#x000b1;0.1</td><td align="left" rowspan="1" colspan="1">1&#x000b1;0.6</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C57BL/6 Silica</bold></td><td align="left" rowspan="1" colspan="1">87&#x000b1;18<xref ref-type="table-fn" rid="nt104">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">17&#x000b1;6.4<xref ref-type="table-fn" rid="nt104">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">64&#x000b1;35<xref ref-type="table-fn" rid="nt104">&#x0002a;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C57BL/6 Silica&#x0002b;BAY</bold></td><td align="left" rowspan="1" colspan="1">60&#x000b1;12<xref ref-type="table-fn" rid="nt104">&#x0002a;</xref><xref ref-type="table-fn" rid="nt105">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">8&#x000b1;0.1<xref ref-type="table-fn" rid="nt104">&#x0002a;</xref><xref ref-type="table-fn" rid="nt105">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">25&#x000b1;11<xref ref-type="table-fn" rid="nt104">&#x0002a;</xref><xref ref-type="table-fn" rid="nt105">&#x02020;</xref></td></tr></tbody></table><table-wrap-foot><fn id="nt104"><label>&#x0002a;</label><p>Statistically significant different when compared to control-treated mice.</p></fn><fn id="nt105"><label>&#x02020;</label><p>Statistically significant different when compared to silica exposed mice.</p></fn></table-wrap-foot></table-wrap><p>To achieve lung epithelial cell-specific inhibition of NF-&#x003ba;B activation, we used mice in which dominant-negative I&#x003ba;B&#x003b1; (dnI&#x003ba;B&#x003b1;:NFKBIA) mutant protein <xref ref-type="bibr" rid="pone.0005689-Brockman1">&#x0005b;15&#x0005d;</xref> is targeted to epithelial cells under the control of the rat Clara cell secretory protein (CCSP: Scgb1a1) or the human surfactant protein C (SPC:SFTPC) promoter respectively. These dnI&#x003ba;B&#x003b1; mutant mice, the mutant protein is resistant to phosphorylation and proteosomal degradation <xref ref-type="bibr" rid="pone.0005689-Brockman1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Skerrett1">&#x0005b;16&#x0005d;</xref> and inhibit NF-&#x003ba;B activation in those cells in which the transgene is expressed (<xref ref-type="fig" rid="pone-0005689-g006">Figure 6</xref>). To confirm that that NF-&#x003ba;B activation was impaired in the epithelium of these mice we isolated Clara or alveolar epithelial type II cells from these transgenic mice and non-transgenic littermate controls following exposure to silica. In vivo exposure (28 d) to silica readily induced NF-&#x003ba;B activation in Clara (<xref ref-type="fig" rid="pone-0005689-g006">Figure 6</xref>) or alveolar epithelial type II cells isolated from the littermate wild-type mice (not shown). In contrast, this NF-&#x003ba;B activation is greatly reduced in Clara or alveolar epithelial type II cells isolated from CCSP- or SPC-dnI&#x003ba;B&#x003b1; mice (<xref ref-type="fig" rid="pone-0005689-g006">Figure 6</xref>).</p><fig id="pone-0005689-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005689.g006</object-id><label>Figure 6</label><caption><title>Expression of a dominant-negative (dn) I&#x003ba;B&#x003b1; protein inhibits epithelial activation of NF-&#x003ba;B in response to silica.</title><p>Lung sections from CCSP-dnI&#x003ba;B&#x003b1; transgenic mice were stained with antibodies against the modified (dnI&#x003ba;B&#x003b1;) I&#x003ba;B&#x003b1; peptide. Panel A shows strong staining in Clara cells of a dnI&#x003ba;B&#x003b1; transgenic mouse. Staining with the same antibody is absent in the non-transgenic littermate mouse in panel B. DNA binding activity of NF-&#x003ba;B in crude nuclear extracts from Clara (C) cells isolated from the lungs of CCSP-dnI&#x003ba;B&#x003b1; transgenic mice, or their littermate (wild-type) 28 days after exposure to silica or saline as controls as described in <xref ref-type="sec" rid="s2">Methods</xref> section. Excess probe represents NF-&#x003ba;B binding in nuclear extract from Clara isolated from silica-exposed littermate wild type mice, assayed in the presence of excess unlabelled oligonucleotide as a competitor. Antibody supershifts were performed using the nuclear extract from Clara cells isolated form silica-exposed littermate wild type mouse as described in <xref ref-type="sec" rid="s2">Methods</xref> section.</p></caption><graphic xlink:href="pone.0005689.g006"/></fig><p>CCSP-dnI&#x003ba;B&#x003b1; mice reacted to silica exposure with decreased lung inflammation as compared to littermate controls (<xref ref-type="table" rid="pone-0005689-t004">Table 4</xref>). This attenuated inflammatory response was associated decreased TNF&#x003b1; transcripts and inflammatory cell infiltration &#x0005b;(Vv(f)&#x0005d; at 28 d after silica exposure (<xref ref-type="table" rid="pone-0005689-t004">Table 4</xref>). In contrast to these effects on inflammation, lung hydroxyproline deposition increased in CCSP-dnI&#x003ba;B&#x003b1; mice than in littermate controls (<xref ref-type="table" rid="pone-0005689-t004">Table 4</xref>). Similarly, CCSP-dnI&#x003ba;B&#x003b1; mice and wild-type littermate mice had nearly equivalent increases in collagen and TIMP1 transcripts. However, silica-induced lung MMP2 transcripts were less in CCSP-dnI&#x003ba;B&#x003b1; mice as compared to C57BL/6 mice (<xref ref-type="fig" rid="pone-0005689-g007">Figure 7</xref>). Because NF-&#x003ba;B can function as an anti-apoptotic factor, we evaluated the effect of expressing the dnI&#x003ba;B&#x003b1; mutant in the lung epithelium of these transgenic mice. CCSP-dnI&#x003ba;B&#x003b1; mice had increased apoptosis (TUNEL positive cells) in their lungs when compared to their non-transgenic littermate controls (<xref ref-type="table" rid="pone-0005689-t004">Table 4</xref>). SPC-dnI&#x003ba;B&#x003b1; mice reacted to silica exposure similar to that of CCSP-dnI&#x003ba;B&#x003b1; mice. SPC-dnI&#x003ba;B&#x003b1; mice had decreased infiltrating cells, but accumulated increased hydroxyproline and TUNEL positive cells in their lungs when compared to littermate controls (<xref ref-type="table" rid="pone-0005689-t005">Table 5</xref>).</p><fig id="pone-0005689-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005689.g007</object-id><label>Figure 7</label><caption><title>Clara cell expression of a dominant-negative (dn) I&#x003ba;B&#x003b1; protein alters TNF&#x003b1;, and MMP2, but not &#x003b1;1(I) collagen and TIMP-1, mRNA expression in response to silica.</title><p>Densitometry analysis of Northern blots of TNF, &#x003b1;1(I) collagen, MMP2, TIMP-1, and 18S (loading control) mRNA expression in CCSP-dnI&#x003ba;B mouse lung 28 days following the intratracheal injection of saline as control, or silica as described in the <xref ref-type="sec" rid="s2">Methods</xref> section. Compared to their wild type littermates, CCSP-dnIkB transgenic mice significantly inhibited (P&#x0003c;0.05) the enhanced expression of TNF&#x003b1; and MMP2 mRNA induced by silica in the mouse lung. Figure illustrate results obtained from five set of mice exposed to silica or saline as control. &#x0002a; Indicates statistically significant difference compared to saline treated mice. &#x02020; Indicates statistically significant difference compared to wild-type non-transgenic mice.</p></caption><graphic xlink:href="pone.0005689.g007"/></fig><table-wrap id="pone-0005689-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005689.t004</object-id><label>Table 4</label><caption><title>Silica Induced Lung Injury in CCSP-dnIKB&#x003b1; mice.</title></caption><graphic id="pone-0005689-t004-4" xlink:href="pone.0005689.t004"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005689-t004-4"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Treatment Condition n&#x0200a;&#x0003d;&#x0200a;5 mice/group</td><td align="left" rowspan="1" colspan="1">Hydroxyproline (&#x000b5;g/Left Lung)</td><td align="left" rowspan="1" colspan="1">Volume-Density Fibrosis Vv (&#x00025;f)</td><td align="left" rowspan="1" colspan="1">TUNEL-Positive cells (per mm<sup>2</sup>)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>NT Littermate Control</bold></td><td align="left" rowspan="1" colspan="1">39.7&#x000b1;4.0</td><td align="left" rowspan="1" colspan="1">4&#x000b1;0.7</td><td align="left" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CCSP-dnI&#x003ba;B Control</bold></td><td align="left" rowspan="1" colspan="1">60&#x000b1;2</td><td align="left" rowspan="1" colspan="1">2&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>NT Littermate Silica</bold></td><td align="left" rowspan="1" colspan="1">76&#x000b1;3<xref ref-type="table-fn" rid="nt106">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">12&#x000b1;3<xref ref-type="table-fn" rid="nt106">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">26&#x000b1;8<xref ref-type="table-fn" rid="nt106">&#x0002a;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>CCSP-dnI&#x003ba;B Silica</bold></td><td align="left" rowspan="1" colspan="1">85&#x000b1;5<xref ref-type="table-fn" rid="nt106">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">7&#x000b1;0.5<xref ref-type="table-fn" rid="nt106">&#x0002a;</xref><xref ref-type="table-fn" rid="nt107">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">46&#x000b1;1<xref ref-type="table-fn" rid="nt106">&#x0002a;</xref><xref ref-type="table-fn" rid="nt107">&#x02020;</xref></td></tr></tbody></table><table-wrap-foot><fn id="nt106"><label>&#x0002a;</label><p>Statistically significant different when compared to control-treated mice.</p></fn><fn id="nt107"><label>&#x02020;</label><p>Statistically significant different when compared to silica exposed NT littermate mice.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0005689-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005689.t005</object-id><label>Table 5</label><caption><title>Silica Induced Lung Injury in SPC-dnI&#x003ba;B&#x003b1; mice.</title></caption><graphic id="pone-0005689-t005-5" xlink:href="pone.0005689.t005"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005689-t005-5"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Treatment Condition n&#x0200a;&#x0003d;&#x0200a;6 mice/group</td><td align="left" rowspan="1" colspan="1">Hydroxyproline (&#x000b5;g/Left Lung)</td><td align="left" rowspan="1" colspan="1">Volume-Density Fibrosis Vv (&#x00025;f)</td><td align="left" rowspan="1" colspan="1">TUNEL-Positive cells (per mm<sup>2</sup>)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>NT Littermate Control</bold></td><td align="left" rowspan="1" colspan="1">47&#x000b1;2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>SPC-dnI&#x003ba;B Control</bold></td><td align="left" rowspan="1" colspan="1">51&#x000b1;9</td><td align="left" rowspan="1" colspan="1">2&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>NT Littermate Silica</bold></td><td align="left" rowspan="1" colspan="1">97&#x000b1;10<xref ref-type="table-fn" rid="nt108">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">25&#x000b1;4</td><td align="left" rowspan="1" colspan="1">27&#x000b1;14</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>SPC-dnI&#x003ba;B Silica</bold></td><td align="left" rowspan="1" colspan="1">117&#x000b1;7<xref ref-type="table-fn" rid="nt108">&#x0002a;</xref><xref ref-type="table-fn" rid="nt109">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">18&#x000b1;4<xref ref-type="table-fn" rid="nt108">&#x0002a;</xref><xref ref-type="table-fn" rid="nt109">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">48&#x000b1;18<xref ref-type="table-fn" rid="nt108">&#x0002a;</xref><xref ref-type="table-fn" rid="nt109">&#x02020;</xref></td></tr></tbody></table><table-wrap-foot><fn id="nt108"><label>&#x0002a;</label><p>Statistically significant different when compared to control-treated mice.</p></fn><fn id="nt109"><label>&#x02020;</label><p>Statistically significant different when compared to silica exposed NT littermate mice.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>Silicosis remains a severe lung disease for which no successful treatment is available. Here, we report that silica exposure leads to large portion of the lung replaced by coalescing nodules with proximal TNF&#x003b1; expressing macrophage and NF-&#x003ba;B activation in epithelial cells. We also found that patients with silicosis had poor survival and experienced early rejection of their lung grafts following lung transplantation. Using a mouse experimental model of silicosis in which the endotracheal instillation of silica reproduces the silica-induced inflammation observed in humans we show that systemic inhibition of NF-&#x003ba;B activation with a pharmacologic inhibitor (BAY 11-7085) of I&#x003ba;B&#x003b1; (NFKBIA) phosphorylation significantly decreases silica induced inflammation and fibrosis, with reduced collagen deposition and apoptosis. In contrast, transgenic mice expressing a dominant negative I&#x003ba;B&#x003b1; mutant protein under the control of epithelial specific promoters demonstrate enhanced collagen deposition and apoptosis in their lungs in response to silica.</p><p>The worldwide incidence and prevalence of silicosis is uncertain, but is increasing in developing countries <xref ref-type="bibr" rid="pone.0005689-WHO1">&#x0005b;29&#x0005d;</xref>. In the United States the incidence and prevalence of silicosis is under-estimated as silicosis is not a reportable disease and under recognized <xref ref-type="bibr" rid="pone.0005689-Goodwin1">&#x0005b;30&#x0005d;</xref>. Approximately 1.7 million people in the US are occupationally exposed to silica <xref ref-type="bibr" rid="pone.0005689-OSHA1">&#x0005b;31&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005689-Morbidity1">&#x0005b;34&#x0005d;</xref> and as many as 119,000 are exposed above permissible levels <xref ref-type="bibr" rid="pone.0005689-OSHA1">&#x0005b;31&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005689-Morbidity1">&#x0005b;34&#x0005d;</xref> with the majority of these individuals employed in mining, construction or maritime activities. Consequently, an estimated 3,600&#x02013;7,300 newly recognized silicosis cases in the US from 1987 to 1996 <xref ref-type="bibr" rid="pone.0005689-OSHA1">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Yassin1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Morbidity1">&#x0005b;34&#x0005d;</xref>. Although preventive measures have significantly decreased the mortality attributable to silica the reality is that that a large number of silica-exposed patients are still dying as a result of this disease <xref ref-type="bibr" rid="pone.0005689-Morbidity1">&#x0005b;34&#x0005d;</xref>. While mortality is widely spread across the country, nine states reported high rates of mortality, more than 2&#x02013;3 deaths/million people/year, with clusters of counties where mining is an important activity contributing disproportionably (&#x0003e;14.8 deaths/million/year) to this mortality <xref ref-type="bibr" rid="pone.0005689-Morbidity1">&#x0005b;34&#x0005d;</xref>. A global health issue, silicosis levels are rising in developing countries. For example, the silicosis burden in China is growing (with &#x0223c;7&#x02013;10,000 new cases/yr) and is extensive (&#x0003e;500,000 cases resulting in &#x0223c;24,000 deaths/yr) <xref ref-type="bibr" rid="pone.0005689-WHO1">&#x0005b;29&#x0005d;</xref>.</p><p>Once established, silica-induced inflammation progresses even after occupational exposure has ended, a phenomenon clearly reproduced in experimental animals <xref ref-type="bibr" rid="pone.0005689-Porter2">&#x0005b;35&#x0005d;</xref>. Using conventional anti-inflammatory agents does not control silica-induced inflammation and therefore, because of this lack of successful treatment, lung transplantation has been proposed as an effective therapeutic alternative <xref ref-type="bibr" rid="pone.0005689-American1">&#x0005b;1&#x0005d;</xref>. However, very little published data is available to support this postulate. A SLT was reported in a 23-yr male in 1972 with the patient surviving 10 months <xref ref-type="bibr" rid="pone.0005689-Vermeire1">&#x0005b;36&#x0005d;</xref>. More recently, the Copenhagen National Lung Transplant Group reported 4 translation cases, but no discussion of their outcome was available <xref ref-type="bibr" rid="pone.0005689-Burton1">&#x0005b;37&#x0005d;</xref>.</p><p>In this report, we describe our experience at the University of Pittsburgh (a post industrial city located in the heart of the mining industry in Western Pennsylvania) with 11 silicosis patients that received lung transplantation for this disease from 1986&#x02013;2007. The outcome of these patients was contrasted with that of a group of 79 patients that received lung transplantation for IPF, a diffuse parenchymal lung disease for which lung transplantation confers a survival benefit <xref ref-type="bibr" rid="pone.0005689-Thalbut1">&#x0005b;17&#x0005d;</xref>. Our data indicate that patients with silicosis appear to have poor survival and greater rate of graft rejection, despite identical protocols for immunosupression, than patients with IPF following lung transplantation. Our analysis is limited by the small size and more importantly by gender differences in lung transplant survival among patients with IPF. Female IPF patients were transplanted at a younger age and had better survival outcome and lower rejection rates when compared to their male counterparts. The reasons for the gender difference in survival following lung transplantation are unknown and are worthy of additional study.</p><p>To further our understanding of the pathogenesis of silicosis we used well-characterized mouse model in which silica exposure produces lung inflammation and parenchymal nodules comparable to those observed in humans exposed to silica. Using this experimental model, silica induced rapid (with in minutes) and persistent (identified 14 and 28 d after a single intratracheal instillation) activation of NF-&#x003ba;B in the lung and that TNF&#x003b1; receptors greatly contribute to this activation. Previously, TNF&#x003b1; has been implicated as a central mediator in the pathogenesis of silicosis. Piguet et al. reported that the exposure of mice to silica increased lung TNF&#x003b1; mRNA levels <xref ref-type="bibr" rid="pone.0005689-Piguet1">&#x0005b;3&#x0005d;</xref>, which preceded the development of lung inflammation and collagen deposition <xref ref-type="bibr" rid="pone.0005689-Porter1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Ortiz1">&#x0005b;12&#x0005d;</xref>. Furthermore, these investigators were able to abrogate silica-induced inflammation and lung fibrosis with the administration of anti TNF&#x003b1; antibodies or TNF&#x003b1; receptors that antagonized the bioactive TNF&#x003b1; <xref ref-type="bibr" rid="pone.0005689-Piguet1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Piguet2">&#x0005b;38&#x0005d;</xref>. Similarly, we have previously reported that animals deficient in TNF&#x003b1; receptors are protected from silica-induced inflammation and fibrosis <xref ref-type="bibr" rid="pone.0005689-Ortiz1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Ortiz2">&#x0005b;20&#x0005d;</xref>. In humans, compelling evidence indicates that polymorphism of the TNF&#x003b1; gene promoter (TNF-308: denominated TNF-A allele 2) is associated with silicosis disease severity, although not with disease frequency, in South African miners <xref ref-type="bibr" rid="pone.0005689-Corbett1">&#x0005b;39&#x0005d;</xref>.</p><p>TNF&#x003b1; mediates its biologic action by binding to two receptors of tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A: p55) and 1B (TNFRSF1B: p75) <xref ref-type="bibr" rid="pone.0005689-Beutler1">&#x0005b;40&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Bazzoni1">&#x0005b;41&#x0005d;</xref>. In this work we find that TNF&#x003b1; receptors contribute to the canonical activation of NF-&#x003ba;B in the mouse lung in response to silica. Previously, we reported that double TNF&#x003b1; receptor deficient mice failed to activate NF-&#x003ba;B in their lungs in response to silica <xref ref-type="bibr" rid="pone.0005689-Ortiz1">&#x0005b;12&#x0005d;</xref>. Centrally located in the TNF&#x003b1; signal pathway, NF-&#x003ba;B activation mediates the inflammatory and cell survival effects of TNF&#x003b1; and therefore constitutes a logical target for antagonism in silicosis <xref ref-type="bibr" rid="pone.0005689-Chen1">&#x0005b;7&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005689-Sacks1">&#x0005b;13&#x0005d;</xref>. The long-term effects of such inhibition are not well understood.</p><p>The present work underscores the importance of the specificity of the NF-&#x003ba;B antagonism during lung inflammation. Thus, both the inflammatory and fibrotic responses to silica was ameliorated by systemic inhibition of NF-&#x003ba;B activation with BAY-117821, an irreversibly inhibitor of TNF&#x003b1;-induced phosphorylation of I&#x003ba;B in human endothelial cells <xref ref-type="bibr" rid="pone.0005689-Pierce1">&#x0005b;14&#x0005d;</xref>. In contrast, although the lung epithelial cell specific inhibition of NF-&#x003ba;B also reduced TNF&#x003b1; expression and the infiltration of inflammatory cells in the lung, it accentuated the apoptotic process and enhanced the fibrosis response by promoting the deposition of collagen and decreasing the matrix remodeling in the lung in response to silica.</p><p>These data stress two aspects of the pathophysiology of silicosis. The first aspect is that although silica enters the body via the respiratory system it triggers a systemic response characterized by stimulation of bone marrow and the migration of bone marrow-derived cells into the lung <xref ref-type="bibr" rid="pone.0005689-Rich1">&#x0005b;42&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005689-Borges1">&#x0005b;45&#x0005d;</xref>. Published data in experimental models of lung fibrosis indicate that although this response is dominated by migration of neutrophils and lymphocytes <xref ref-type="bibr" rid="pone.0005689-Rich1">&#x0005b;42&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005689-Borges1">&#x0005b;45&#x0005d;</xref> it also includes the homing of profibrotic fibrocytes <xref ref-type="bibr" rid="pone.0005689-Hashimoto1">&#x0005b;46&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005689-Phillips1">&#x0005b;47&#x0005d;</xref>. Characterized by their expression of hematopoietic markers (such as CD45) fibrocytes also express collagen and contribute actively to the deposition of this protein in the lung <xref ref-type="bibr" rid="pone.0005689-Phillips1">&#x0005b;47&#x0005d;</xref>. Mobilization and homing of fibrocytes into the lung is facilitated by their expression of chemokine receptors, such as CXCR4, and the enhanced expression in the injured lung of the cognate ligands for these receptors (i.e., stromal cell derived factor1 alpha and CXCL12). Because expression of these ligands is sensitive to NF-&#x003ba;B regulation <xref ref-type="bibr" rid="pone.0005689-Cherla1">&#x0005b;48&#x0005d;</xref>, early inhibition of the NF-&#x003ba;B activation could reduce the migration of these cells and protect the lung from further injury.</p><p>The second aspect is that epithelial cells responses contribute to inflammation in silicosis. Consistent with this statement, CCSP-dnI&#x003ba;B as well as SPC-dnI&#x003ba;B transgenic mice exhibit reduced TNF&#x003b1; mRNA expression and are less inflamed than their wild-type littermates. However, these mice exhibit more robust accumulation of collagen in response to silica. These data underscore the importance of the epithelial specific inhibition of NF-&#x003ba;B, which has previously been reported to increase MMPs in the lungs of silica-exposed animals depleted of Clara cells <xref ref-type="bibr" rid="pone.0005689-Yatera1">&#x0005b;49&#x0005d;</xref>. In contrast, we find that silica induced expression of the MMP inhibitor, TIMP1, in the lung of mice, and this enhanced expression was not altered in the lungs of the CCSP-dnI&#x003ba;B mice. Therefore, these data suggest that the decrease MMPs expression originated by the Clara cell specific inhibition of NF-&#x003ba;B would create an imbalance of the ability of lung to remodel in favor of matrix deposition. Our data are also consistent with the hypothesis that lung epithelium harbors a small number of stem cells that are resistant to toxins and are fundamental to the maintenance of homeostasis of the lung <xref ref-type="bibr" rid="pone.0005689-Giangreco1">&#x0005b;50&#x0005d;</xref>. Therefore, it is plausible that expression of the I&#x003ba;B repressor under specific epithelial promoters, such as CCSP or SPC, results in reduced activation of NF-&#x003ba;B on these cells rendering them more sensitive to apoptosis thus compromising their ability to repair the injured epithelium.</p><p>In summary, the present work re-emphasizes that silicosis remains a serous lung disease for which no specific treatment is successful. Although limited by its size, our data support that patients with silicosis appear to have poor outcome following lung transplantation. Experimental data indicate that TNF&#x003b1; receptors contribute to the silica-induced activation of NF-&#x003ba;B in the lung and our data suggest that early and systemic antagonism of this signal transduction ameliorates lung inflammation and benefits outcome in experimental silicosis. Because systemic antagonism of TNF&#x003b1; in humans is currently possible with a variety of strategies such as use of antibodies or recombinant receptors that bind and antagonize TNF&#x003b1; it would be appropriate to prospectively study the potential therapeutic role of such antagonism in modulating silica-induced lung injury and improving the outcome of lung transplantation for silicosis.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0005689.s001"><label>Figure S1</label><caption><p>Silica exposed Macrophages express TNF&#x003b1;. High (&#x000d7;400) magnification photomicrograph, using polarized light of the same area illustrated in <xref ref-type="fig" rid="pone-0005689-g003">Figure 3B</xref>, to illustrate that TNF&#x003b1; expression is predominantly located in macrophages laden with bi-refringent silica particles.</p><p>(7.06 MB TIF)</p></caption><media xlink:href="pone.0005689.s001.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005689.s002"><label>Figure S2</label><caption><p>TNF&#x003b1; and NF-&#x003ba;B expression in silicosis. Panel A show photomicrograph (&#x000d7;100) illustrating hematoxyllin and eosin staining of silicotic nodule involving a terminal airway in lung tissue isolated from a silica exposed subject at the time of lung transplantation. Insert (circle) represents an area adjacent to the silicotic nodule to illustrate sequential HE (D &#x000d7;200), and immunohistochemistry staining against TNF&#x003b1; in interstitial macrophages (arrows) loaded with dust (E &#x000d7;200), or nuclear localization on NF-&#x003ba;B in adjacent epithelial cells (E &#x000d7;200).</p><p>(5.84 MB TIF)</p></caption><media xlink:href="pone.0005689.s002.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005689.s003"><label>Figure S3</label><caption><p>The Effect of BAY treatment on silica-induced gene expression in the mouse lung. Northern blot analysis of TNF, &#x003b1;1(I) collagen, TIMP-1, and 18S (loading control) mRNA expression in mouse lung 28 days following the intratracheal injection of saline as control, silica alone, or silica&#x0002b;BAY as described in <xref ref-type="sec" rid="s2">Methods</xref> section. Gel is representative of result obtained with three different sets of animal exposures.</p><p>(0.34 MB TIF)</p></caption><media xlink:href="pone.0005689.s003.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005689.s004"><label>Figure S4</label><caption><p>The effect of systemic or lung epithelial specific NF-&#x003ba;B inhibition on the induction of apoptosis (TUNEL staining) in the lung of silica exposed mice. Apoptosis was characterized by terminal deoxynucleotidyltransferase dUTP nick end-labeling (TUNEL) as described in <xref ref-type="sec" rid="s2">Methods</xref> section. The panels show low (&#x000d7;100) power magnification photomicrographs of the lung obtained from lung tissues of C57BL/6 mice exposed to saline as control (A), silica (B), silica&#x0002b;BAY (D), or SPC-dnI&#x003ba;B transgenic mouse (E) exposed to silica as described in the <xref ref-type="sec" rid="s2">Method</xref> section. Panel C show high (&#x000d7;400) magnification of TUNEL positive cells identified in B. Panel F illustrates negative staining (by omission of treatment with deoxynucleotidyltransferase enzyme) of a silica-exposed tissue used as control to demonstrate stain specificity.</p><p>(10.28 MB TIF)</p></caption><media xlink:href="pone.0005689.s004.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005689.s005"><label>Table S1</label><caption><p>(0.07 MB DOC)</p></caption><media xlink:href="pone.0005689.s005.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005689.s006"><label>Methods S1</label><caption><p>File containing description of supplemental methods</p><p>(0.05 MB DOC)</p></caption><media xlink:href="pone.0005689.s006.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors have no conflicting financial interest. The authors would like to acknowledge Dr. Christopher Wilson, at the Department of Immunology at the University of Washington in Seattle, for his kind gift of SPC-dnI&#x003ba;B&#x003b1; mice.</p></ack><ref-list><title>References</title><ref id="pone.0005689-American1"><label>1</label><citation citation-type="journal"><collab>American Thoracic Society Statement</collab><year>1997</year><article-title>Adverse effects of crystalline silica exposure.</article-title><source>Am J Respir Crit Care Med</source><volume>155</volume><fpage>761</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">9032226</pub-id></citation></ref><ref id="pone.0005689-Mossman1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mossman</surname><given-names>BT</given-names></name><name><surname>Churg</surname><given-names>A</given-names></name></person-group><year>1998</year><article-title>Mechanisms in the pathogenesis of asbestosis and silicosis.</article-title><source>Am J Respir Crit Care Med</source><volume>157</volume><fpage>1666</fpage><lpage>1680</lpage><pub-id pub-id-type="pmid">9603153</pub-id></citation></ref><ref id="pone.0005689-Piguet1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piguet</surname><given-names>PF</given-names></name><name><surname>Collart</surname><given-names>MA</given-names></name><name><surname>Grau</surname><given-names>GE</given-names></name><name><surname>Sappino</surname><given-names>AP</given-names></name><name><surname>Vassalli</surname><given-names>P</given-names></name></person-group><year>1990</year><article-title>Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis.</article-title><source>Nature</source><volume>344</volume><fpage>245</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">2156165</pub-id></citation></ref><ref id="pone.0005689-Baeuerle1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baeuerle</surname><given-names>PA</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><year>1996</year><article-title>NF-&#x003ba;B: ten years after.</article-title><source>Cell</source><volume>87</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">8858144</pub-id></citation></ref><ref id="pone.0005689-Hoffman1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>A</given-names></name><name><surname>Levchenko</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>ML</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><year>2002</year><article-title>The I&#x003ba;B-NF-&#x003ba;B signaling module: temporal control and selective gene activation.</article-title><source>Science</source><volume>298</volume><fpage>1241</fpage><lpage>1245</lpage><pub-id pub-id-type="pmid">12424381</pub-id></citation></ref><ref id="pone.0005689-Perkins1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perkins</surname><given-names>ND</given-names></name></person-group><year>2007</year><article-title>Integrating cell-signalling pathways with NF-&#x003ba;B and IKK function.</article-title><source>Nature Reviews</source><volume>8</volume><fpage>49</fpage><lpage>62</lpage></citation></ref><ref id="pone.0005689-Chen1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name></person-group><year>2002</year><article-title>NF-kappaB, a pivotal transcription factor in silica-induced diseases.</article-title><source>Mol Cell Biochem</source><volume>234/235</volume><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">12162430</pub-id></citation></ref><ref id="pone.0005689-Schins1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schins</surname><given-names>RP</given-names></name><name><surname>McAlinden</surname><given-names>A</given-names></name><name><surname>McNee</surname><given-names>W</given-names></name><name><surname>Jimenez</surname><given-names>LA</given-names></name><name><surname>Guy</surname><given-names>K</given-names></name><etal/></person-group><year>2000</year><article-title>Persistent depletion of I kappa B alpha and interleukin-8-expression in human pulmonary epithelial cells exposed to quartz particles.</article-title><source>Toxicol Appl Pharmacol</source><volume>167</volume><fpage>107</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">10964761</pub-id></citation></ref><ref id="pone.0005689-Kang1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>JL</given-names></name><name><surname>Pack</surname><given-names>IS</given-names></name><name><surname>Hong</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Castranova</surname><given-names>V</given-names></name></person-group><year>2000</year><article-title>Silica induces Nucler factor-&#x003ba;B activation trough tyrosine phosphorylation of I&#x003ba;B&#x003b1; in RAW264.7 macrophages.</article-title><source>Toxicol Appl Pharmacol</source><volume>169</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">11076697</pub-id></citation></ref><ref id="pone.0005689-Hubbard1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hubbard</surname><given-names>AK</given-names></name><name><surname>Timblin</surname><given-names>CR</given-names></name><name><surname>Shukla</surname><given-names>A</given-names></name><name><surname>Rincon</surname><given-names>M</given-names></name><name><surname>Mossman</surname><given-names>BT</given-names></name></person-group><year>2002</year><article-title>Activation of NF-&#x003ba;B dependent gene expression by silica in lungs of luciferase reporter mice.</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><volume>282</volume><fpage>L968</fpage><lpage>L975</lpage><pub-id pub-id-type="pmid">11943661</pub-id></citation></ref><ref id="pone.0005689-Porter1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>DW</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Barger</surname><given-names>M</given-names></name><name><surname>Robinson</surname><given-names>VA</given-names></name><etal/></person-group><year>2002</year><article-title>Time course of pulmonary response of rats to inhalation of crystalline silica: NF-&#x003ba;B activation, inflammation, cytokine production, and damage.</article-title><source>Inhalation Toxicology</source><volume>14</volume><fpage>349</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">12028809</pub-id></citation></ref><ref id="pone.0005689-Ortiz1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ortiz</surname><given-names>LA</given-names></name><name><surname>Lasky</surname><given-names>JA</given-names></name><name><surname>Gozal</surname><given-names>E</given-names></name><name><surname>Lungarella</surname><given-names>G</given-names></name><name><surname>Cavarra</surname><given-names>E</given-names></name><etal/></person-group><year>2001</year><article-title>Tumor necrosis factor receptor deficiency alters metalloproteinase 13/tissue inhibitor of metalloproteinase 1 expression in murine silicosis.</article-title><source>Am J Respir Crit Care Med</source><volume>163</volume><fpage>244</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">11208652</pub-id></citation></ref><ref id="pone.0005689-Sacks1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sacks</surname><given-names>M</given-names></name><name><surname>Gordon</surname><given-names>J</given-names></name><name><surname>Bylander</surname><given-names>J</given-names></name><name><surname>Porter</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>XL</given-names></name><etal/></person-group><year>1998</year><article-title>Silica-induced pulmonary inflammation in rats: activation of NF-&#x003ba;B and suppression by dexamethasone.</article-title><source>Biochem Biophys Res Commun</source><volume>253</volume><fpage>181</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">9875241</pub-id></citation></ref><ref id="pone.0005689-Pierce1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>JW</given-names></name><name><surname>Schoenleber</surname><given-names>R</given-names></name><name><surname>Jesmok</surname><given-names>G</given-names></name><name><surname>Best</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>SA</given-names></name><etal/></person-group><year>1997</year><article-title>Novel inhibitors of cytokine-induced I&#x003ba;B&#x003b1; phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo.</article-title><source>J Biol Chem</source><volume>272</volume><fpage>21096</fpage><lpage>21103</lpage><pub-id pub-id-type="pmid">9261113</pub-id></citation></ref><ref id="pone.0005689-Brockman1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brockman</surname><given-names>JA</given-names></name><name><surname>Scherer</surname><given-names>DC</given-names></name><name><surname>McKinsey</surname><given-names>TA</given-names></name><name><surname>Hall</surname><given-names>SM</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><etal/></person-group><year>1995</year><article-title>Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation.</article-title><source>Mol Cell Biol</source><volume>15</volume><fpage>2809</fpage><lpage>2818</lpage><pub-id pub-id-type="pmid">7739562</pub-id></citation></ref><ref id="pone.0005689-Skerrett1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skerrett</surname><given-names>SJ</given-names></name><name><surname>Liggitt</surname><given-names>HD</given-names></name><name><surname>Hajjar</surname><given-names>AM</given-names></name><name><surname>Ernst</surname><given-names>RK</given-names></name><name><surname>Miller</surname><given-names>SI</given-names></name><etal/></person-group><year>2004</year><article-title>Respiratory epithelial cells regulate lung inflammation in response to endotoxin.</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><volume>287</volume><fpage>L143</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">15047567</pub-id></citation></ref><ref id="pone.0005689-Thalbut1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thalbut</surname><given-names>G</given-names></name><name><surname>Mal</surname><given-names>H</given-names></name><name><surname>Castier</surname><given-names>Y</given-names></name><name><surname>Groussard</surname><given-names>O</given-names></name><name><surname>Brugi&#x000e8;re</surname><given-names>O</given-names></name><etal/></person-group><year>2003</year><article-title>Survival benefit of lung transplantation for patients with Idiopathic pulmonary fibrosis.</article-title><source>J Thoracic and Cardiovascular Surgery</source><volume>126</volume><fpage>469</fpage><lpage>474</lpage></citation></ref><ref id="pone.0005689-1"><label>18</label><citation citation-type="journal"><article-title>Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). American Thoracic Society (2000)</article-title><source>Am J Respir Crit Care Med</source><volume>161</volume><fpage>646</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">10673212</pub-id></citation></ref><ref id="pone.0005689-2"><label>19</label><citation citation-type="journal"><article-title>American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. (2002). This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by ERS Executive Committee, June 2001.</article-title><source>Am J Respir Crit Care Med</source><volume>165</volume><fpage>277</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">11790668</pub-id></citation></ref><ref id="pone.0005689-Ortiz2"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ortiz</surname><given-names>LA</given-names></name><name><surname>Lasky</surname><given-names>JA</given-names></name><name><surname>Lungarella</surname><given-names>G</given-names></name><name><surname>Cavarra</surname><given-names>E</given-names></name><name><surname>Martorana</surname><given-names>P</given-names></name><etal/></person-group><year>1999</year><article-title>Upregulation of the p75 but not the p55 mRNA during silica and bleomycin-induced lung injury in mice.</article-title><source>Am J Respir Cell Mol Biol</source><volume>20</volume><fpage>825</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">10101016</pub-id></citation></ref><ref id="pone.0005689-Hoyle1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoyle</surname><given-names>GW</given-names></name><name><surname>Graham</surname><given-names>RM</given-names></name><name><surname>Finkelstein</surname><given-names>JB</given-names></name><name><surname>Nguyen</surname><given-names>K-PT</given-names></name><name><surname>Gozal</surname><given-names>D</given-names></name><etal/></person-group><year>1998</year><article-title>Hyperinnervation of the Airways in Transgenic Mice Overexpressing Nerve Growth Factor.</article-title><source>Am J Respir Cell Mol Biol</source><volume>18</volume><fpage>149</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">9476901</pub-id></citation></ref><ref id="pone.0005689-Cavarra1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cavarra</surname><given-names>E</given-names></name><name><surname>Martorana</surname><given-names>PA</given-names></name><name><surname>Bartelesi</surname><given-names>B</given-names></name><name><surname>Fineschi</surname><given-names>S</given-names></name><name><surname>Gambelli</surname><given-names>F</given-names></name><etal/></person-group><year>2001</year><article-title>Genetic deficiency of &#x003b1;1-PI in mice influences lung responses to bleomcyin.</article-title><source>Eur Respir J</source><volume>17</volume><fpage>474</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">11405528</pub-id></citation></ref><ref id="pone.0005689-Gambelli1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gambelli</surname><given-names>F</given-names></name><name><surname>Friedman</surname><given-names>M</given-names></name><name><surname>Hammond</surname><given-names>T</given-names></name><name><surname>Riches</surname><given-names>D</given-names></name><name><surname>Ortiz</surname><given-names>LA</given-names></name></person-group><year>2004</year><article-title>Phosphorylation of Tumor Necrosis Factor Receptor 1 (p55) protects macrophages from silica-induced apoptosis.</article-title><source>J Biol Chem</source><volume>279(3)</volume><fpage>2020</fpage><lpage>2029</lpage><pub-id pub-id-type="pmid">14570868</pub-id></citation></ref><ref id="pone.0005689-Corti1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>M</given-names></name><name><surname>Brody</surname><given-names>AR</given-names></name><name><surname>Harrison</surname><given-names>JH</given-names></name></person-group><year>1996</year><article-title>Isolation and primary culture of murine alveolar type II cells.</article-title><source>Am J Respir Cell Mol Biol</source><volume>14</volume><fpage>309</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">8600933</pub-id></citation></ref><ref id="pone.0005689-Warshamana1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warshamana</surname><given-names>SG</given-names></name><name><surname>Corti</surname><given-names>M</given-names></name><name><surname>Brody</surname><given-names>AR</given-names></name></person-group><year>2001</year><article-title>TNF-&#x003b1;, PDGF, and TGF-&#x003b2;<sub>1</sub> Expression by Primary Mouse Bronchiolar-Alveolar Epithelial and Mesenchymal Cells: TNF-&#x003b1; Induces TGF-&#x003b2;<sub>1</sub>.</article-title><source>Experimental and Molecular Pathology</source><volume>71</volume><fpage>13</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">11502094</pub-id></citation></ref><ref id="pone.0005689-Gozal1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gozal</surname><given-names>E</given-names></name><name><surname>Ortiz</surname><given-names>LA</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Burow</surname><given-names>M</given-names></name><name><surname>Lasky</surname><given-names>JA</given-names></name><etal/></person-group><year>2002</year><article-title>Silica-induced apoptosis in murine macrophage: involvement of TNF-&#x003b1; and NF-&#x003ba;B activation.</article-title><source>Am J Respir Cell Mol Biol</source><volume>27</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">12091251</pub-id></citation></ref><ref id="pone.0005689-Kuwano1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuwano</surname><given-names>K</given-names></name><name><surname>Hagimoto</surname><given-names>N</given-names></name><name><surname>Kawasaki</surname><given-names>M</given-names></name><name><surname>Yatomi</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>N</given-names></name><etal/></person-group><year>1999</year><article-title>Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis.</article-title><source>J Clin Invest</source><volume>104</volume><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">10393694</pub-id></citation></ref><ref id="pone.0005689-Estenne1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Estenne</surname><given-names>M</given-names></name><name><surname>Maurer</surname><given-names>JR</given-names></name><name><surname>Boehler</surname><given-names>A</given-names></name><name><surname>Egan</surname><given-names>JJ</given-names></name><name><surname>Frost</surname><given-names>A</given-names></name><etal/></person-group><year>2002</year><article-title>Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria.</article-title><source>J Heart Lung Transplant</source><volume>21</volume><fpage>297</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">11897517</pub-id></citation></ref><ref id="pone.0005689-WHO1"><label>29</label><citation citation-type="book"><collab>WHO Health Organization</collab><year>2000</year><source>Silicosis. WHO Fact Sheet No. 238</source><publisher-loc>Geneva, Switzerland</publisher-loc><publisher-name>WHO</publisher-name></citation></ref><ref id="pone.0005689-Goodwin1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>SS</given-names></name><name><surname>Stanbury</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>ML</given-names></name><name><surname>Silbergeld</surname><given-names>E</given-names></name><name><surname>Parker</surname><given-names>JE</given-names></name></person-group><year>2003</year><article-title>Previously undetected silicosis in New Jersey decedents.</article-title><source>Am J Ind Med</source><volume>2003 Sep;44(3)</volume><fpage>304</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">12929151</pub-id></citation></ref><ref id="pone.0005689-OSHA1"><label>31</label><citation citation-type="journal"><collab>OSHA</collab><year>2003</year><article-title>Occupational exposure to crystalline silica. Semiannual regulatory agenda.</article-title><source>Fed Reg</source><volume>68</volume><fpage>30583</fpage><lpage>30594</lpage><comment>Available at <ext-link ext-link-type="uri" xlink:href="http://www.osha.gov/SLT/silicacrystalline/standards.html">http://www.osha.gov/SLT/silicacrystalline/standards.html</ext-link> &#x0005b;Revised 27 September 2004&#x0005d;</comment></citation></ref><ref id="pone.0005689-Rosenman1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenman</surname><given-names>KD</given-names></name><name><surname>Reilly</surname><given-names>MJ</given-names></name><name><surname>Henneberger</surname><given-names>PK</given-names></name></person-group><year>2003</year><article-title>Estimating the total number of newly recognized silicosis cases in the United States.</article-title><source>Am J Ind Med</source><volume>44</volume><fpage>141</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">12874846</pub-id></citation></ref><ref id="pone.0005689-Yassin1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yassin</surname><given-names>A</given-names></name><name><surname>Yebesi</surname><given-names>F</given-names></name><name><surname>Tingle</surname><given-names>R</given-names></name></person-group><year>2005</year><article-title>Occupational exposure to crystalline silica dust in the United States, 1988&#x02013;2003.</article-title><source>Environ Health Perspect</source><volume>113</volume><fpage>255</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">15743711</pub-id></citation></ref><ref id="pone.0005689-Morbidity1"><label>34</label><citation citation-type="other"><collab>Morbidity and Mortality weekly Report (MMWR)</collab><year>2005</year><article-title>Silicosis Mortality, Prevention, and Control-United States 1968&#x02013;2002.</article-title><comment>April 29, 2005/Vol 54/No 16; <ext-link ext-link-type="uri" xlink:href="http://www2a.cdc.gov/drds/WorldReportData/">http://www2a.cdc.gov/drds/WorldReportData/</ext-link></comment></citation></ref><ref id="pone.0005689-Porter2"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>DW</given-names></name><name><surname>Hubbs</surname><given-names>AF</given-names></name><name><surname>Mercer</surname><given-names>R</given-names></name><name><surname>Robinson</surname><given-names>VA</given-names></name><name><surname>Ramsey</surname><given-names>D</given-names></name><etal/></person-group><year>2004</year><article-title>Progression of lung inflammation and damage in rats after cessation of silica inhalation.</article-title><source>Toxicological Sciences</source><volume>79</volume><fpage>370</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">15056817</pub-id></citation></ref><ref id="pone.0005689-Vermeire1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vermeire</surname><given-names>P</given-names></name><name><surname>Tasson</surname><given-names>J</given-names></name><name><surname>Lamont</surname><given-names>H</given-names></name><name><surname>Barbier</surname><given-names>F</given-names></name><name><surname>Versieck</surname><given-names>J</given-names></name><etal/></person-group><year>1972</year><article-title>Respiratory function after lung homotransplantations with a ten-month survival in man.</article-title><source>Am Rev Resp Dis</source><volume>106</volume><fpage>515</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">4562138</pub-id></citation></ref><ref id="pone.0005689-Burton1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>CM</given-names></name><name><surname>Milman</surname><given-names>N</given-names></name><name><surname>Carlsen</surname><given-names>J</given-names></name><name><surname>Arendrup</surname><given-names>H</given-names></name><name><surname>Eliasen</surname><given-names>K</given-names></name><etal/></person-group><year>2005</year><article-title>The Copenhagen National Lung Transplant Group: Survival after Single Lung, Double Lung, and Hearth-Lung Transplantation.</article-title><source>J Heart Lung Transplant</source><volume>24</volume><fpage>1834</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16297790</pub-id></citation></ref><ref id="pone.0005689-Piguet2"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piguet</surname><given-names>PF</given-names></name><name><surname>Vesin</surname><given-names>C</given-names></name></person-group><year>1994</year><article-title>Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice.</article-title><source>Eur Respir J</source><volume>7</volume><fpage>515</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">7516893</pub-id></citation></ref><ref id="pone.0005689-Corbett1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corbett</surname><given-names>EL</given-names></name><name><surname>Mozzato-Chamay</surname><given-names>N</given-names></name><name><surname>Butterworth</surname><given-names>AE</given-names></name><name><surname>De Cock</surname><given-names>KM</given-names></name><name><surname>Williams</surname><given-names>BG</given-names></name><etal/></person-group><year>2002</year><article-title>Polymorphisms in the tumor necrosis factor-alpha gene promoter may predispose to severe silicosis in black South African miners.</article-title><source>Am J Respir Crit Care Med</source><volume>165(5)</volume><fpage>690</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">11874815</pub-id></citation></ref><ref id="pone.0005689-Beutler1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>B</given-names></name><name><surname>Van Huffel</surname><given-names>C</given-names></name></person-group><year>1994</year><article-title>Unraveling function in the TNF ligand and receptor families.</article-title><source>Science</source><volume>265</volume><fpage>667</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">8171316</pub-id></citation></ref><ref id="pone.0005689-Bazzoni1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bazzoni</surname><given-names>F</given-names></name><name><surname>Beutler</surname><given-names>B</given-names></name></person-group><year>1996</year><article-title>The tumor necrosis factor ligand and receptor families.</article-title><source>NEJM</source><volume>334</volume><fpage>1717</fpage><lpage>1725</lpage><pub-id pub-id-type="pmid">8637518</pub-id></citation></ref><ref id="pone.0005689-Rich1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rich</surname><given-names>IN</given-names></name><name><surname>Heit</surname><given-names>W</given-names></name><name><surname>Kubanek</surname><given-names>B</given-names></name></person-group><year>1980</year><article-title>An erytropietic stimulating factor similar to erythropoietin released by macrophages after treatment with silica.</article-title><source>Blut</source><volume>40(5)</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">6249431</pub-id></citation></ref><ref id="pone.0005689-Fulop1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fulop</surname><given-names>GM</given-names></name><name><surname>Osmond</surname><given-names>DG</given-names></name></person-group><year>1983</year><article-title>Regulation of bone marrow lymphocyte production. IV. Cells mediating the stimulation of marrow lymphocyte production by sheep red blood cells: studies in anti-IgM-suppressed mice, athymic mice, and silica-treated mice.</article-title><source>Cell Immunol</source><volume>75</volume><fpage>91</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">6297807</pub-id></citation></ref><ref id="pone.0005689-Langley1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langley</surname><given-names>RJ</given-names></name><name><surname>Kalra</surname><given-names>R</given-names></name><name><surname>Mishra</surname><given-names>NC</given-names></name><name><surname>Hahn</surname><given-names>FF</given-names></name><name><surname>Razani-Boroujerdi</surname><given-names>S</given-names></name><etal/></person-group><year>2004</year><article-title>A biphasic Response to Silica. I. Immunostimulation is restricted to the early stage of silicosis in Lewis rats.</article-title><source>Am J Respir Cell Mol Biol</source><volume>30</volume><fpage>823</fpage><lpage>829</lpage><pub-id pub-id-type="pmid">14742293</pub-id></citation></ref><ref id="pone.0005689-Borges1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borges</surname><given-names>VM</given-names></name><name><surname>Falc&#x000e3;o</surname><given-names>H</given-names></name><name><surname>Leite-J&#x000fa;nior</surname><given-names>JH</given-names></name><name><surname>Alvim</surname><given-names>L</given-names></name><name><surname>Teixeira</surname><given-names>GP</given-names></name><etal/></person-group><year>2001</year><article-title>Fas ligand triggers pulmonary silicosis.</article-title><source>J Exp Med</source><volume>194</volume><fpage>155</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">11457890</pub-id></citation></ref><ref id="pone.0005689-Hashimoto1"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>N</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Chensue</surname><given-names>SW</given-names></name><name><surname>Phan</surname><given-names>SH</given-names></name></person-group><year>2004</year><article-title>Bone marrow-derived progenitor cells in pulmonary fibrosis.</article-title><source>J Clin Invest</source><volume>113</volume><fpage>243</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">14722616</pub-id></citation></ref><ref id="pone.0005689-Phillips1"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>RJ</given-names></name><name><surname>Burdick</surname><given-names>MD</given-names></name><name><surname>Hong</surname><given-names>K</given-names></name><name><surname>Lutz</surname><given-names>MA</given-names></name><name><surname>Murray</surname><given-names>LA</given-names></name><etal/></person-group><year>2004</year><article-title>Circulating fibrocytes traffic to the lung in response to CXCL12 and mediate fibrosis.</article-title><source>J Clin Invest</source><volume>114</volume><fpage>438</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">15286810</pub-id></citation></ref><ref id="pone.0005689-Cherla1"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cherla</surname><given-names>RP</given-names></name><name><surname>Ganju</surname><given-names>RK</given-names></name></person-group><year>2001</year><article-title>Stromal cell-derived factor 1 alpha-induced chemotaxis in T cells is mediated by nitric oxide signalling pathways.</article-title><source>J Immunol</source><volume>166</volume><fpage>3067</fpage><lpage>3074</lpage><pub-id pub-id-type="pmid">11207257</pub-id></citation></ref><ref id="pone.0005689-Yatera1"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yatera</surname><given-names>K</given-names></name><name><surname>Morimoto</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>HN</given-names></name><name><surname>Yamato</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>I</given-names></name><etal/></person-group><year>2001</year><article-title>Increased expression of matrix metalloproteinase in Clara cell-ablated mice inhaling crystalline silica.</article-title><source>Environ Health Perspect</source><volume>109</volume><fpage>795</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">11564614</pub-id></citation></ref><ref id="pone.0005689-Giangreco1"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giangreco</surname><given-names>A</given-names></name><name><surname>Reynolds</surname><given-names>SD</given-names></name><name><surname>Stripp</surname><given-names>BR</given-names></name></person-group><year>2002</year><article-title>Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction.</article-title><source>Am J Pathol</source><volume>161</volume><fpage>173</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">12107102</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>United States Public Health Service Grants ES10859, HL071953 (to L.A. Ortiz) and HL073745 (to NK) and by a generous donation of the Simmons family. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 